大行評級 | 美銀證券:下調保險股目標價,行業首選友邦保險
格隆匯12月14日丨美銀證券發表研究報告指出,中國保險業今年增長仍然疲弱,保費增長放緩,續保率低,利潤下降。至於中國目前正進行的養老金改革,相信可爲險企提供更好的機會,客戶一旦意識到養老金產品的重要性,估計有關趨勢可能會持續數年。而隨着行業增長放緩,預期中國監管機構將轉向推出更多支援措施。
此外,該行仍然首選友邦(1299.HK),認爲其與內地同業相比,其於市場、客戶及渠道方面仍有業務擴張機會,即使持續受疫情影響,公司跨區域營運令增長更具彈性。至於中資保險公司中,該行看好太保(2601.HK)及國壽(2628.HK),太保目標價由36港元降至34港元,國壽目標價由19.3港元降至18.5港元,兩股皆爲“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.